GGrantIndex
← Search

ASSESSMENT OF ENDOGENOUS AND CAR T-CELL IMMUNITY FOLLOWING ANTI-PD-1 AGENT AS A TRANSITION STEP TO PHASE 2 COMBINATION IMMUNOTHERAPY

$1,177,565FY2019Department of the ArmyDOD

Sloan-Kettering Institute For Cancer Research

Investigators

View source on USAspending →
ASSESSMENT OF ENDOGENOUS AND CAR T-CELL IMMUNITY FOLLOWING ANTI-PD-1 AGENT AS A TRANSITION STEP TO PHASE 2 COMBINATION IMMUNOTHERAPY · GrantIndex